Unjoni Ewropea - Malti - EMA (European Medicines Agency)

united therapeutics europe ltd - dinutuximab - neuroblastoma - aġenti antineoplastiċi - unituxin huwa indikat għat-trattament ta ' riskju għoli neuroblastoma fil-pazjenti l-età ta ' 12-il xahar li 17years, li kienu riċevuti induzzjoni chemotherapy qabel u miksub mill-inqas tweġiba parzjali, segwita minn terapija myeloablative u ċelluli staminali awtologi trapjant (asct). jingħata flimkien ma 'fattur li jistimula l-kolonja tal-granuloċit-makrofagi (gm-csf), interleukin-2 (il-2), u isotretinoin.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - ranolazine - angina pectoris - terapija kardijaka - ranexa huwa indikat bħala żieda terapija għall-trattament sintomatiċi tal-pazjenti ma stabbli anġina pectoris li ma jirriżultax kontrollati jew intolerant għal terapiji kontra d-anginal tal-linja ta ' l-ewwel (bħal beta-blockers u / jew tal-kalċju antagonisti).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare bv - abacavir, lamivudine - infezzjonijiet ta 'hiv - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - kivexa huwa indikat fit-terapija kombinata antiretrovirali għat-trattament ta 'infezzjoni tal-virus ta' immunodefiċjenza umana (hiv) f'adulti, adolexxenti u tfal li jiżnu mill-inqas 25 kg. qabel ma tinbeda kura b'abacavir, screening għall-ġarr ta ' l-allel hla-b*5701 għandhom isiru fi kwalunkwe pazjent infettat bl-hiv, irrispettavament mir-razza. abacavir m'għandux jintuża f'pazjenti magħrufa li jġorru l-allel hla-b*5701.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rifjut ta 'graft - immunosoppressanti - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nova laboratories ireland limited - 6-mercaptopurine monohydrate - lewkimja, limfoma - aġenti antineoplastiċi - xaluprine huwa indikat għall-kura ta 'lewkimja limfoblastika akuta (all) f'adulti, adolexxenti u tfal.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - epatite Ċ, kronika - antivirali għal użu sistemiku - victrelis huwa indikat għall-kura ta ' l-infezzjoni tal-ġenotip-1 kronika epatite-c (chc), flimkien mal-peginterferon alfa u ribavirin, fil-pazjenti adulti b ' mard tal-fwied kompensat li huma mhux ittrattat minn qabel jew li jkunu fallew terapija qabel.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - voriconazole - aspergillosis; candidiasis; mycoses - antimikotiċi għall-użu sistemiku-derivattivi tat-triazole - voriconazole huwa aġent broad-spectrum, aġent antifungali triazole u hija indikata fl-adulti u t-tfal li għandhom sentejn u aktar kif ġej:trattament ta 'asperġillożi invażiva;it-trattament ta'candidaemia f'pazjenti mhux newtropeniċi;il-kura ta' fluconazole-'infezzjonijiet invażivi serji candida reżistenti (inkluż c. krusei);il-kura ta'infezzjonijiet fungali serji kkawżati minn scedosporium spp. u fusarium spp. voriconazole għandu jingħata primarjament lil pazjenti b'progressiva, possibbilment ta'theddida għall-ħajja infezzjonijiet.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - disturbi relatati ma 'opjojdi - drogi oħra tas-sistema nervuża - trattament ta 'sostituzzjoni għal dipendenza fuq id-droga opioid, fi ħdan qafas ta' trattament mediku, soċjali u psikoloġiku. l-intenzjoni tal-komponent ta 'naloxone hija li tiskoraġġixxi l-użu ħażin minn ġol-vina. il-kura hija maħsuba għall-użu f'adulti u adolexxenti ta 'aktar minn 15-il sena li qablu li jiġu ttrattati għall-vizzju.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

indivior europe limited - buprenorphine, naloxone - disturbi relatati ma 'opjojdi - drogi oħra tas-sistema nervuża - trattament ta 'sostituzzjoni għal dipendenza fuq opioid-drug, fi ħdan qafas ta' trattament mediku, soċjali u psikoloġiku. l-intenzjoni tal-komponent ta 'naloxone hija li tiskoraġġixxi l-użu ħażin minn ġol-vina. il-kura hija maħsuba għall-użu f'adulti u adolexxenti ta 'aktar minn 15-il sena li qablu li jiġu ttrattati għall-vizzju.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.